V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10420154 | 10041330 | 1.69 | 78 | Palliative (P) | null | 2016-09-17 | Sorafenib | N | N | LANREOTIDE | 100985170 |
| 10420372 | 10041332 | 1.75 | 96 | null | 2019-07-22 | 2019-08-02 | Trastuzumab | 02 | null | DABRAFENIB | 101838865 |
| 10420420 | 10041334 | 1.75 | 74.8 | Adjuvant (A) | 2019-03-19 | 2019-03-19 | THALIDOMIDE | 02 | N | LENVATINIB | 101685822 |
| 10420481 | 10041335 | 1.62 | 47 | 03 | 2019-10-03 | 2019-10-14 | Dasatinib | 02 | N | AML18 TRIAL | 101347468 |
| 10420483 | 10041336 | 0 | 0 | Curative (C) | 2019-07-19 | 2019-07-25 | Irinotecan + Modified De Gramont | 02 | N | TRANSPLANT ALEMTUZUMAB + CYCLOPHOSPHAMIDE + FLUDARABINE (+/- TBI) | 100661160 |
| 10420539 | 10041337 | 1.75 | 76.5 | Neo-adjuvant (N) | 2020-01-09 | 2020-01-20 | Obinutuzumab + Venetoclax | 02 | N | DABRAFENIB | 100961715 |
| 10420578 | 10041338 | 0 | 100.7 | 03 | null | 2019-07-10 | LANREOTIDE | null | N | APALUTAMIDE | 101850349 |
| 10420589 | 10041339 | 1.75 | 95 | Curative (C) | 2019-07-24 | 2019-08-26 | ABVD | 02 | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100271492 |
| 10420614 | 10041340 | 1.63 | 63 | Palliative (P) | 2017-10-01 | 2017-10-09 | Cape+Cisplatin+Trastuzumab Load | 02 | N | AFATINIB | 101164902 |
| 10420691 | 10041342 | null | 0 | Curative (C) | 2019-09-04 | 2019-09-04 | PACLITAXEL + TRASTUZUMAB | 02 | null | CISPLATIN + DOCETAXEL + FLUOROURACIL | 101456989 |
| 10420763 | 10041345 | 1.69 | 96 | Palliative (P) | 2019-03-08 | 2019-03-10 | ECX | 02 | N | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 100620821 |
| 10420873 | 10041346 | null | null | Palliative (P) | 2016-12-24 | 2017-01-08 | FEC 100 + DOCETAXEL | 02 | N | STAMPEDE TRIAL | 100769892 |
| 10420884 | 10041347 | 1.75 | 80.5 | Neo-adjuvant (N) | null | 2018-05-06 | ECX | null | N | GEMCITABINE + NAB-PACLITAXEL | 101818491 |
| 10420886 | 10041348 | 1.8 | 52.4 | Curative (C) | 2016-12-01 | 2016-12-01 | IDELALISIB | 02 | N | SORAFENIB | 100580460 |
| 10420893 | 10041349 | 1.69 | 83 | Palliative (P) | 2018-10-22 | 2018-10-23 | null | 02 | N | BRIGATINIB | 101535454 |
| 10420914 | 10041350 | 1.8 | 67.3 | 03 | 2018-01-22 | 2018-02-12 | RIALTO TRIAL | 02 | null | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 100852732 |
| 10420917 | 10041351 | null | null | Curative (C) | 2017-01-07 | 2017-01-07 | Bortezomib + Daratumumab | 02 | N | PACLITAXEL + TRASTUZUMAB | 101278696 |
| 10420940 | 10041352 | 1.66 | 71 | Curative (C) | 2019-11-14 | 2019-11-26 | Irinotecan + Modified De Gramont | 02 | N | THALIDOMIDE | 101187386 |
| 10421080 | 10041356 | 1.6 | 83.8 | 03 | 2018-03-02 | 2018-03-02 | CYCLO + RITUXIMAB + VINCRISTINE | null | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100973788 |
| 10421272 | 10041357 | 1.64 | 74 | Disease modification (D) | 2020-07-24 | 2020-08-17 | CHOP - 14 days | 02 | null | SORAFENIB | 100250658 |
| 10421285 | 10041358 | 1.7 | 91.65 | null | 2019-10-18 | 2019-10-31 | Apalutamide | 02 | N | SAPROCAN TRIAL | 101001243 |
| 10421383 | 10041359 | 1.66 | 70 | Palliative (P) | 2021-12-09 | 2021-12-09 | Vinorelbine (oral) | N | null | DOXORUBICIN EMBOLISATION | 100858300 |
| 10421408 | 10041360 | null | 0 | null | 2019-12-24 | 2020-01-08 | CAPECITABINE + CARBOPLATIN + Cetuximab | 02 | null | BENDAMUSTINE + OBINUTUZUMAB | 100424030 |
| 10421469 | 10041361 | 1.72 | 75.5 | Curative (C) | 2017-02-13 | 2017-02-13 | IDELALISIB + RITUXIMAB | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101295028 |
| 10421544 | 10041363 | 1.49 | 58 | Curative (C) | null | 2018-06-18 | Bexarotene | N | N | MUK 6 TRIAL | 101766393 |
| 10421566 | 10041365 | 1.69 | 72 | Curative (C) | 2019-06-09 | 2019-06-10 | ECX | 02 | null | CLARITY TRIAL | 100888438 |
| 10421650 | 10041367 | 1.56 | 41.3 | null | 2018-11-26 | 2018-11-26 | TALIMOGENE LAHERPAREPVEC | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101465884 |
| 10421817 | 10041370 | null | null | Palliative (P) | 2018-06-04 | 2018-06-18 | Cisplatin + Pembrolizumab + Pemetrexed | 02 | null | BLEOMYCIN | 100457819 |
| 10421854 | 10041372 | 1.7 | 154 | Palliative (P) | 2017-06-23 | 2017-06-23 | Melphalan IV High dose | 02 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 100849989 |
| 10421856 | 10041373 | 1.7 | 77 | 03 | 2019-06-07 | 2019-06-13 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100249863 |
| 10421958 | 10041376 | 1.68 | 83 | 03 | null | 2019-12-26 | TRASTUZUMAB | null | null | FLUOROURACIL + MITOMYCIN + RT | 100596182 |
| 10421984 | 10041377 | 1.58 | 75.7 | Curative (C) | 2020-05-05 | 2020-05-05 | PENTOSTATIN + RITUXIMAB | null | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 100144954 |
| 10422018 | 10041378 | 1.79 | 64.1 | Palliative (P) | 2021-09-12 | 2021-09-21 | MPT | 02 | null | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101841355 |
| 10422086 | 10041379 | 1.73 | 0 | 03 | 2018-11-01 | 2018-11-15 | Doxorubicin + Ifosfamide | 02 | N | IDELALISIB + RITUXIMAB | 101009525 |
| 10422137 | 10041381 | 1.51 | 51.8 | Curative (C) | 2018-03-17 | 2018-03-17 | MATRIX (lymphoma) | N | null | OCTREOTIDE | 100469433 |
| 10422194 | 10041382 | 1.84 | 68.8 | Palliative (P) | 2017-02-23 | 2017-02-27 | GemCarbo Days 1+8 | 02 | N | GEMCITABINE + NAB-PACLITAXEL | 100340854 |
| 10422204 | 10041383 | 1.64 | 84.5 | Curative (C) | 2015-08-25 | 2015-08-25 | BUBBLE Trial | 02 | N | RALTITREXED | 101292116 |
| 10422213 | 10041384 | null | null | null | 2021-04-15 | 2021-05-06 | Cisplatin + Radiotherapy | 02 | null | LENALIDOMIDE + RITUXIMAB | 101302380 |
| 10422234 | 10041386 | 0 | null | 03 | 2017-05-30 | 2017-06-15 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | CABOZANTINIB | 101395029 |
| 10422305 | 10041389 | 0 | 0 | Curative (C) | 2017-08-27 | 2017-08-27 | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 02 | N | IDELALISIB + RITUXIMAB | 100263951 |
| 10422311 | 10041390 | 1.58 | 51.8 | Palliative (P) | 2020-05-23 | 2020-06-14 | Abemaciclib + Letrozole | 02 | null | DASATINIB | 101108068 |
| 10422447 | 10041393 | 1.68 | 93.7 | Neo-adjuvant (N) | 2017-01-28 | 2017-02-14 | RCEOP | 02 | N | BUSULPHAN | 100159418 |
| 10422449 | 10041394 | 1.78 | 65 | Curative (C) | 2019-04-23 | 2019-04-24 | TRASTUZUMAB EMTANSINE | 02 | N | CYCLOPHOSPHAMIDE | 100484608 |
| 10422522 | 10041395 | 1.73 | 85 | 03 | 2018-03-08 | 2018-03-09 | LENVATINIB | N | null | FLAIR TRIAL | 100023453 |
| 10422545 | 10041396 | null | 72 | Palliative (P) | 2017-10-01 | 2017-10-15 | Rituximab + Venetoclax | 02 | N | ISATUXIMAB + POMALIDOMIDE | 101696199 |
| 10422666 | 10041398 | 1.7 | 51.4 | 03 | 2017-12-06 | 2017-12-09 | BLEOMYCIN | N | N | CVD | 101804266 |
| 10422815 | 10041401 | 1.84 | 79 | null | 2019-10-05 | 2019-10-20 | FEC 60 or 75 | 02 | null | CETUXIMAB | 100798178 |
| 10423076 | 10041404 | 1.74 | 51.4 | null | 2019-12-29 | 2020-01-05 | TALIMOGENE LAHERPAREPVEC | 02 | null | LENVATINIB | 100293820 |
| 10423089 | 10041405 | 1.87 | 69.5 | Curative (C) | 2017-11-28 | 2019-08-02 | null | 02 | N | BORTEZOMIB + DARATUMUMAB | 101646647 |
| 10423155 | 10041408 | 1.68 | 0 | Not known (9) | 2017-12-25 | 2018-01-01 | Melphalan IV High dose | 01 | N | CYTARABINE + FLUDARABINE + IDARUBICIN | 101394410 |